Capper Joseph H 4

What Happened

• Joseph H. Capper, a director of TELA Bio, received four equity grants on June 9, 2026: two restricted stock unit (RSU) awards (11,925 and 11,675 shares) and two derivative awards (17,550 and 17,335 share-equivalent stock options). All awards were granted at $0.00 (i.e., no cash paid).
• In total the awards cover 58,485 share-equivalents (23,600 RSUs and 34,885 in option/derivative form). These are compensation awards (not open-market purchases or sales).

Key Details

• Transaction date: June 9, 2026; filing date: June 11, 2026 (filed within the typical two-business-day Form 4 window).
• Grant prices: $0.00 for all items (awards/grants).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Vesting terms (from filing footnotes):
  • 11,925 RSUs vest in three equal annual installments beginning June 9, 2027 (subject to continued service). (F1)
  • 11,675 RSUs vest on the earlier of June 9, 2027, the next annual meeting, or a Change in Control (subject to continued service). (F2)
  • 17,550 option vests in 36 equal monthly installments beginning June 9, 2026 (subject to continued service). (F3)
  • 17,335 option vests on the earlier of June 9, 2027, the next annual meeting, or a Change in Control (subject to continued service). (F4)

Context

• These were compensation awards (RSUs and options) issued to a director and typically reflect long-term incentive alignment rather than an insider buying or selling stock. Awards vest over time or on certain corporate events and require continued service to the company.
• The derivative entries represent options or other instruments that, once vested and exercised under plan terms, could convert into common shares; the filing does not indicate any immediate sale or cashless exercise.